Question 266 of 433
Why is it so hard to prove a longevity drug works?
The short answer
Because the outcome that matters, living longer, takes decades to measure, and “aging” is not an official disease that regulators recognize.
A trial in 50-year-olds would need to run for thirty years. So researchers use shortcuts: biomarkers, clocks, or delay of the first major disease. The shortcuts can mislead. This year’s Lp(a) result is the perfect example: a drug improved the number beautifully and did not improve the outcome. Until better shortcuts are validated, be skeptical of any treatment whose only evidence is that it “reversed biological age.”
“This book is for education. It is not medical advice, and reading it does not make you my patient or create a doctor-patient relationship.” From the book’s medical disclaimer. Full disclaimer
TRIAL-DESIGN PRINCIPLE — Biomarkers and clinical outcomes differ; a failed drug is not a universal test of a biological mechanism.Evidence grade (draft mapping)JClinical judgment / author synthesisPart 18, Q266 · Sources: R9
Sources cited
- R9 Novartis. Lp(a)HORIZON phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease. September 4, 2026. Link pending verification
From Longevity Unmasked by Afshine Ash Emrani, MD, FACC. Medical disclaimer. This book is for education. It is not medical advice, and reading it does not make you my patient or create a doctor-patient relationship. Nothing here is meant to diagnose, treat, cure, or prevent any disease. Medicine is personal: a test, drug, supplement, or exercise plan that helps one person can harm another. Do not start, stop, or change any medication or treatment because of something you read in these pages. Talk with a licensed clinician who knows your history first. If you think you are having a medical emergency, call 911. The author disclaims responsibility for any loss or harm arising from use of the information in this book.